Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor

Allergy and Asthma Proceedings

Volumn 37, Issue 2, 2016, Pages 164-170

  Farkas, Henriette ^a   Kohalmi, Kinga V ^a   Veszeli, Nóra ^a   Zotter, Zsuzsanna ^a,b   Várnai, Katalin ^c   Varga, Lilian ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^b Medical Center of State   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; TRANEXAMIC ACID;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ARTERY THROMBOSIS; ARTICLE; CHILD; COHORT ANALYSIS; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; VEIN THROMBOSIS; ANGIOEDEMAS, HEREDITARY; COMPLICATION; HEALTH CARE SURVEY; MIDDLE AGED; PRESCHOOL CHILD; RISK; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOEDEMAS, HEREDITARY; CHILD; CHILD, PRESCHOOL; COMPLEMENT C1 INHIBITOR PROTEIN; FEMALE; HEALTH CARE SURVEYS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK; THROMBOEMBOLISM; TIME FACTORS; YOUNG ADULT;

EID: 84959505492     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2016.37.3933     Document Type: Article

References (32)

1. Cicardi M, Aberer W, Banerji A, et al. Classification, diagnosis, and approach to treatment for angioedema: Consensus report from the Hereditary Angioedema International Working Group. Allergy 69:602-616, 2014.
2. Kaplan AP, and Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 47:2161-2169, 2010.
3. Cugno M, Cicardi M, Bottasso B, et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 89:3213-3218, 1997.
4. Farkas H. Current pharmacotherapy of bradykinin-mediated angioedema. Expert Opin Pharmacother 14:571-586, 2013.
5. Bork K. Human pasteurized C1-inhibitor concentrate for the treatment of hereditary angioedema due to C1-inhibitor deficiency. Expert Rev Clin Immunol 7:723-733, 2011.
6. Gompels MM, and Lock RJ. Cinryze (C1-inhibitor) for the treatment of hereditary angioedema. Expert Rev Clin Immunol 7:569-573, 2011.
7. Varga L, and Farkas H. rhC1INH: A new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol 7:143-153, 2011.
8. Moldovan D, Bernstein JA, and Cicardi M. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. Immunotherapy 7:739-752, 2015.
9. Duffey H, and Firszt R. Management of acute attacks of hereditary angioedema: Role of ecallantide. J Blood Med 6:115-123, 2015.
10. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 363:532-541, 2010.
11. Cinryze (C1 esterase inhibitor [human]) [package insert]. New York: Lev Pharmaceuticals Inc; 2008.
12. Berinert (C1 esterase inhibitor [human]) [package insert]. Marburg, Germany: CSL Behring GmbH; 2009.
13. Arzneimittelkommission der Deutschen Aertzteschaft. Schwerwiegende Thrombenbildung nach Berinert HS. Dtsch Aerztebl 97:B-864, 2000.
14. Farkas H, and Varga L. The Hungarian HAE experience. Transfus Apher Sci 29:229-233, 2003.
15. Previtali E, Bucciarelli P, Passamonti SM, and Martinelli I. Risk factors for venous and arterial thrombosis. Blood Transfus 9:120-138, 2011.
16. Horstick G, Berg O, Heimann A, et al. Application of C1-esterase inhibitor during reperfusion of ischemic myocardium: Dose-related beneficial versus detrimental effects. Circulation 104:3125-3131, 2001.
17. Farkas H, Csuka D, Toth F, et al. Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages. Eur J Obstet Gynecol Reprod Biol 165:366-367, 2012.
18. Buehler PW. Pharmacology/Toxicology Review Memorandum. STN 125267 - C1 Esterase Inhibitor for the treatment of human angioedema (HAE). Department of Health and Human Services Food and Drug Administration Center for Biologics Evaluation and Research. August, 2007. Available online at http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/UCM229783.pdf; accessed May 22, 2013.
19. Tassani P, Kunkel R, Richter JA, et al. Effect of C1-esterase-inhibitor on capillary leak and inflammatory response syndrome during arterial switch operations in neonates. J Cardiothorac Vasc Anesth 15:469-473, 2001.
20. Schurmann D, Herzog E, Raquet E, et al. C1-esterase inhibitor treatment: Preclinical safety aspects on the potential prothrombotic risk. Thromb Haemost 112:960-971, 2014.
21. Relan A, Bakhtiari K, van Amersfoort ES, et al. Recombinant C1-inhibitor: Effects on coagulation and fibrinolysis in patients with hereditary angioedema. BioDrugs 26:43-52, 2012.
22. Baskin JL, Pui CH, Reiss U, et al. Management of occlusion and thrombosis associated with long-term indwelling central venous catheters. Lancet 374:159-169, 2009.
23. Kalaria S, and Craig T. Assessment of hereditary angioedema treatment risks. Allergy Asthma Proc 34:519-522, 2013.
24. Gandhi PK, Gentry WM, and Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: Investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 32:902-909, 2012.
25. Crowther M, Bauer KA, and Kaplan AP. The thrombogenicity of C1 esterase inhibitor (human): Review of the evidence. Allergy Asthma Proc 35:444-453, 2014.
26. Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: A decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 120:941-947, 2007.
27. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: Consensus report of an International Working Group. Allergy 67:147-157, 2012.
28. Cinryze US Prescribing Information. Available online at http://www.cinryze.com/pdfs/cinryze-prescribing-information.pdf; accessed 2015.
29. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 124:801-808, 2009.
30. Berinert US Prescribing Information. Available online at http://labeling.cslbehring.com/PI/US/Berinert/EN/Berinert-PrescribingInformation.pdf; accessed 2015.
31. Bork K. An evidence based therapeutic approach to hereditary and acquired angioedema. Curr Opin Allergy Clin Immunol 14:354-362, 2014.
32. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 26:709-724, 2006.